JP2025510815A - 抗ｐａｒ２抗体 - Google Patents

抗ｐａｒ２抗体 Download PDF

Info

Publication number
JP2025510815A
JP2025510815A JP2024556630A JP2024556630A JP2025510815A JP 2025510815 A JP2025510815 A JP 2025510815A JP 2024556630 A JP2024556630 A JP 2024556630A JP 2024556630 A JP2024556630 A JP 2024556630A JP 2025510815 A JP2025510815 A JP 2025510815A
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
antibody
par2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024556630A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510815A5 (https=
Inventor
ハッチングス，キャサリン
オズボーン，グレッグ
シュレンカー，オリバー
オクラザ，クシシトフ
ジューコフ，アンドレイ
シュミット，アニカ
クラウス，アレクサンドラ
リューレ，ドロティー
Original Assignee
ネクセラファーマ ユーケー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネクセラファーマ ユーケー リミテッド filed Critical ネクセラファーマ ユーケー リミテッド
Publication of JP2025510815A publication Critical patent/JP2025510815A/ja
Publication of JP2025510815A5 publication Critical patent/JP2025510815A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024556630A 2022-03-24 2023-03-24 抗ｐａｒ２抗体 Pending JP2025510815A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2204159.4A GB202204159D0 (en) 2022-03-24 2022-03-24 Antibodies
GB2204159.4 2022-03-24
PCT/GB2023/050760 WO2023180767A1 (en) 2022-03-24 2023-03-24 Anti-par2 antibodies

Publications (2)

Publication Number Publication Date
JP2025510815A true JP2025510815A (ja) 2025-04-15
JP2025510815A5 JP2025510815A5 (https=) 2026-03-31

Family

ID=81449405

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024556630A Pending JP2025510815A (ja) 2022-03-24 2023-03-24 抗ｐａｒ２抗体

Country Status (10)

Country Link
US (1) US20250313621A1 (https=)
EP (1) EP4499694A1 (https=)
JP (1) JP2025510815A (https=)
KR (1) KR20240161970A (https=)
CN (1) CN119137152A (https=)
AU (1) AU2023238937A1 (https=)
CA (1) CA3246035A1 (https=)
GB (1) GB202204159D0 (https=)
IL (1) IL315704A (https=)
WO (1) WO2023180767A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024255639A1 (en) * 2023-04-14 2025-10-02 Triveni Bio, Inc. Dual inhibitor trypsin antibodies and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2327382T3 (es) 1999-07-20 2009-10-29 Morphosys Ag Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
US7888482B2 (en) * 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
MX2019010802A (es) 2017-03-16 2019-10-30 Medimmune Ltd Anticuerpos anti-par2 y usos de los mismos.
SMT202500106T1 (it) * 2020-08-18 2025-05-12 Cephalon Llc Anticorpi anti-par-2 e loro metodi d'uso

Also Published As

Publication number Publication date
WO2023180767A1 (en) 2023-09-28
CA3246035A1 (en) 2023-09-28
CN119137152A (zh) 2024-12-13
US20250313621A1 (en) 2025-10-09
GB202204159D0 (en) 2022-05-11
KR20240161970A (ko) 2024-11-13
AU2023238937A1 (en) 2024-10-31
EP4499694A1 (en) 2025-02-05
IL315704A (en) 2024-11-01

Similar Documents

Publication Publication Date Title
AU2019349651B2 (en) SIRP alpha binding proteins and methods of use thereof
JP2023531989A (ja) Ｃｃｒ８抗体及びその使用
CN112566662A (zh) 针对cd47的阻断抗体及其使用方法
WO2014016737A9 (en) Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof
KR102523150B1 (ko) 항-테나신 c 항체 및 이의 용도
WO2017156298A1 (en) Ilt7 binding molecules and methods of using the same
JP2024535692A (ja) 抗ｈｌａ－ｇ抗体
JP2023536631A (ja) 多重特異性結合性作用剤およびその使用
CN116194482A (zh) Tigit和cd112r阻断
JP2024505674A (ja) 抗ｉｌ１ｒａｐ抗体
JP2025510815A (ja) 抗ｐａｒ２抗体
JP7796005B2 (ja) 抗ｔｒｅｍ－１抗体およびその使用
JP2023536629A (ja) Ｃｄ４７結合性作用剤およびその使用
JP2023536630A (ja) Ｐｄ－ｌ１結合性作用剤およびその使用
JP2023512304A (ja) Ｋｌｋ５に対する抗体
TW202600594A (zh) 結合構築體(一)
WO2026072909A2 (en) Flt1 binding proteins and methods of use
KR20260005790A (ko) 항-blt1 항체 및 이의 용도
HK40107886A (zh) 抗ccr8抗体疗法：生物标志物和组合疗法
HK40091263A (zh) 用於治疗应用的ccr8抗体
HK40090308A (zh) 抗ccr8抗体疗法：生物标志物和组合疗法
BR122024025431B1 (pt) Uso de um anticorpo anti-ccr8 em combinação simultânea, separada ou sequencial com um ou mais compostos terapeuticamente ativos adicionais para induzir adcp em um paciente humano com um tumor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260323